Two of the leading companies in the AI drug development field, Recursion Pharmaceuticals and Exscientia, said Thursday that they will merge into one company. The new company will continue using the ...
It's not looking too good for the biotech.
Recursion Pharmaceuticals uses AI to expedite the laborious process of developing drugs. The company could benefit from industry-wide regulatory changes as well as its own clinical progress. However, ...
Recursion Pharmaceuticals had a busy start to the week, scrapping a rare disease asset from its pipeline as part of a strategic rethink while pulling in a $150 million private placement. The ...